Privileged Scaffolds for Potent and Specific Inhibitors of Mono-ADP-Ribosylating PARPs

The identification of new targets to address unmet medical needs, better in a personalized way, is an urgent necessity. The introduction of PARP1 inhibitors into therapy, almost ten years ago, has represented a step forward this need being an innovate cancer treatment through a precision medicine ap...

Full description

Bibliographic Details

Published in:	Molecules
Main Authors:	Maria Giulia Nizi, Chiara Sarnari, Oriana Tabarrini
Format:	Article
Language:	English
Published:	MDPI AG 2023-08-01
Subjects:	PARPs PARPs inhibitors (PARPi) mono-ARTDs selective inhibitors chemical probes
Online Access:	https://www.mdpi.com/1420-3049/28/15/5849